Reata Pharmaceuticals, Inc. Class A Common Stock (RETA)

RETA was delisted on the 25th of September, 2023.

• Market cap: $6.57B
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

Employees: 323